Mark William  Lowdell net worth and biography

Mark Lowdell Biography and Net Worth

Insider of INmune Bio
Prof. Lowdell has been a Chief Scientific Officer and Chief Manufacturing Officer since the formation of the Company in September 2015.   Prof. Lowdell is Professor of Cell and Tissue Therapy at University College London, where he has led a translational immunotherapy group since 1994.  Since February 2009, Prof. Lowdell has also been Director of Cellular Therapy at the Royal Free London NHS Foundation Trust.   He received his PhD in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

What is Mark William Lowdell's net worth?

The estimated net worth of Mark William Lowdell is at least $17.45 million as of July 7th, 2021. Dr. Lowdell owns 1,500,401 shares of INmune Bio stock worth more than $17,449,664 as of March 28th. This net worth evaluation does not reflect any other assets that Dr. Lowdell may own. Additionally, Dr. Lowdell receives an annual salary of $152,010.00 as Insider at INmune Bio. Learn More about Mark William Lowdell's net worth.

How old is Mark William Lowdell?

Dr. Lowdell is currently 61 years old. There are 2 older executives and no younger executives at INmune Bio. The oldest executive at INmune Bio is Dr. Raymond Joseph Tesi M.D., Co-Founder, President, CEO, Chief Medical Officer & Chairman, who is 68 years old. Learn More on Mark William Lowdell's age.

What is Mark William Lowdell's salary?

As the Insider of INmune Bio, Inc., Dr. Lowdell earns $152,010.00 per year. There are 2 executives that earn more than Dr. Lowdell. The highest earning executive at INmune Bio is Dr. Raymond Joseph Tesi M.D., Co-Founder, President, CEO, Chief Medical Officer & Chairman, who commands a salary of $591,500.00 per year. Learn More on Mark William Lowdell's salary.

How do I contact Mark William Lowdell?

The corporate mailing address for Dr. Lowdell and other INmune Bio executives is 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037. INmune Bio can also be reached via phone at (858) 964-3720 and via email at [email protected]. Learn More on Mark William Lowdell's contact information.

Has Mark William Lowdell been buying or selling shares of INmune Bio?

Mark William Lowdell has not been actively trading shares of INmune Bio during the last quarter. Most recently, Mark William Lowdell sold 701 shares of the business's stock in a transaction on Wednesday, November 3rd. The shares were sold at an average price of $20.00, for a transaction totalling $14,020.00. Learn More on Mark William Lowdell's trading history.

Who are INmune Bio's active insiders?

INmune Bio's insider roster includes Mark Lowdell (Insider), David Moss (CFO), Timothy Schroeder (Director), and Raymond Tesi (CEO). Learn More on INmune Bio's active insiders.

Are insiders buying or selling shares of INmune Bio?

During the last twelve months, INmune Bio insiders bought shares 1 times. They purchased a total of 7,000 shares worth more than $48,650.00. During the last twelve months, insiders at the sold shares 1 times. They sold a total of 10,000 shares worth more than $110,100.00. The most recent insider tranaction occured on November, 10th when Director Scott Juda bought 7,000 shares worth more than $48,650.00. Insiders at INmune Bio own 36.1% of the company. Learn More about insider trades at INmune Bio.

Information on this page was last updated on 11/10/2023.

Mark William Lowdell Insider Trading History at INmune Bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/3/2021Sell701$20.00$14,020.00View SEC Filing Icon  
10/27/2021Sell2,357$20.00$47,140.00View SEC Filing Icon  
10/22/2021Sell400$20.00$8,000.00View SEC Filing Icon  
7/7/2021Sell5,850$20.02$117,117.001,500,401View SEC Filing Icon  
9/11/2019Buy2,918$6.23$18,179.14
See Full Table

Mark William Lowdell Buying and Selling Activity at INmune Bio

This chart shows Mark William Lowdell's buying and selling at INmune Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

INmune Bio Company Overview

INmune Bio logo
INmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Read More

Today's Range

Now: $11.54
Low: $11.28
High: $12.05

50 Day Range

MA: $12.12
Low: $10.53
High: $14.01

2 Week Range

Now: $11.54
Low: $5.87
High: $14.74

Volume

42,253 shs

Average Volume

77,375 shs

Market Capitalization

$207.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99